Radiopharm (RADX) Sees Slight Pessimism From Analysts
Radiopharm Theranostics Limited (NASDAQ:RADX) is a biotechnology company developing treatments for ailments such as brain metastasis and prostate cancer. B.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | SilverArc Capital Devesh Gandhi | 187,406 | $978,259 | 0.14% | |
| 2. | Stonepine Capital Timothy P. Lynch | 51,000,000 | $850,851 | 0.62% | |
| 3. | VGI Partners Robert M. P. Luciano | 90,909 | $474,545 | 0.03% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,000 | $83,520 | 0% | |
| 2. | 14,469 | $75,528 | 0% | |
| 3. | 14,277 | $74,526 | 0% | |
| 4. | 10,285 | $53,688 | 0% | |
| 5. | 14,591 | $76 | 0% |